shall develop a joint action plan, in consultation with health care providers and patient advocates (including relevant Federal advisory committees) that— (1) utilizes data from Medicare claims on how much of a single-use drug was not administered, comparing single-use vial sizes in other countries, and through analysis during the drug approval process of alternative vial size safety and efficacy, to reduce drug waste and better manage costs